Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease – authors' reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|12|1304-1305

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.12, 2015-06, pp. : 1304-1305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 12, 2015-06 ,pp. : 1303-1304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 895-906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications—authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 448-448

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 940-941

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions. Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1134-1134

John Wiley & Sons Inc

Access to resources Recommend Favorite